P120007/S034: Aptima HPV 16 18/45 Genotype Assay
FDA’s recorded scope: Approval for the Aptima HPV 16 18/45 Genotype Assay for expanding the indications to include primary screening.
Explore this company’s associated devices, FDA decisions and regulatory history.

MedtechLedger currently links 4 FDA records to the applicant name Gen-Probe Incorporated. 2 entries are PMA supplements. 2 entries are 30-day notices. These are records held by this publication, rather than a count of the company’s entire portfolio.
The dated entries run from Oct 7, 2025 to Feb 3, 2026. Individual filings may concern different products or changes to an existing application; review the identifier and decision scope on each record.
Product code OYB appears in 4 of the 4 linked filings. The collection spans 1 FDA product code and 2 original PMA application families. These figures describe the filings available here; they do not establish the company’s total device sales or market share.
The largest PMA family in this collection is P100042, with 2 linked entries. Follow the parent application and its dated supplements to distinguish the original device scope from later changes.
Applicant mailing address recorded by FDA: 10210 Genetic Center Dr., San Diego, CA, 92121. Recorded on P120007/S034, decision dated Feb 3, 2026.
FDA’s recorded scope: Approval for the Aptima HPV 16 18/45 Genotype Assay for expanding the indications to include primary screening.
FDA’s recorded scope: The Aptima HPV Assay is an in vitro nucleic acid amplification test for the qualitative detection of E6/E7 viral messenger RNA (mRNA) from 14 high-risk types of human papillomavirus (HPV) in cervical specimens. The high-risk HPV types detected by the assay include: 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68. The Aptima HPV Assay does not differentiate between the 14 high-risk types. Cervical specimens in ThinPrep Pap Test vials containing PreservCyt Solution and collected with broom-type or cytobrush/spatula collection devices* may be tested with the Aptima HPV Assay. The assay is used with the Tigris DTS System or the Panther System.The Aptima HPV Assay is indicated for use for routine cervical cancer screening as per professional medical guidelines, including triage of ASC-US cytology, co-testing (adjunctive screening) with cytology, and HPV primary screening of women to assess the risk for cervical pre-cancer and cancer. Patients should be followed-up in accordance with professional medical guidelines, results from prior screening, medical history, and other risk factors.Primary HPV screening with the Aptima HPV Assay has only been validated on the Panther System.
FDA’s recorded scope: to adjust raw material test method
FDA’s recorded scope: to adjust raw material test method
Subsidiaries and similarly named applicants can have separate records. The links below preserve the applicant and submission identifiers. Source records are linked on each filing.
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Aptima HPV 16 18/45 Genotype AssayP120007/S034 | Gen-Probe Incorporated | PMA supplement | Feb 3, 2026 | FDA |
APTIMA HPV ASSAYP100042/S038 | Gen-Probe Incorporated | PMA supplement | Feb 3, 2026 | FDA |
| Gen-Probe Incorporated | PMA supplement | Oct 7, 2025 | FDA | |
| Gen-Probe Incorporated | PMA supplement | Oct 7, 2025 | FDA |
Source updated Nov 9, 2026. Retrieved Nov 21, 2026.